NWBO stock price forecast has been influenced by heightened retail investor activity in microcap biotech stocks, making price swings more reactive to social sentiment. Yahoo offers you a variety of products and services for little or no cost. We’re able to do this because of our advertising revenue. This also makes it possible to provide certain services and content that would otherwise be unavailable to you through Yahoo services. Northwest Biotherapeutics (NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, held its Annual Shareholders Meeting on June 29, 2024. Over 77% of the total shares voted, with 961.7 million votes cast out of 1.2 billion outstanding shares. Five shareholder proposals were overwhelmingly approved, including the re-election of Class I directors and the ratification of stock options and executive compensation. The company also discussed its progress and future growth opportunities, emphasizing its strong performance since the last meeting. An audio recording of the session is available on the company's website through July 7, 2024. NWBO stock price forecast is cautiously optimistic given low short interest and steady long-term holder retention rates in recent filings.